

# Phyloncology, LLC

## Universal, Non-Invasive Cancer Detection

Revolutionizing Cancer Early Detection & Diagnosis

# Mission & Vision

---

- **Deliver the fastest and most accurate universal cancer detection platform**
- **Enable early detection across cancer types, reduce mortality worldwide, and transform global oncology diagnostics.**





# Problem

---

- **Cancer heterogeneity limits traditional biomarker-based diagnostics**
- **Late detection drives poor outcomes and high costs**
- **Invasive biopsies are inefficient for screening**


# Solution

---

- A patented analytical platform based on **phylogenetics and evolutionary biology** that reveals cancer signatures from complex biological data.

- Non-biomarker dependent approach

- 4 Transforms biological variability into signal



# How It works

---



- Patient provides a blood sample during routine care.



- Standard mass spectrometry generate high-dimensional data (~\$100)



- Data input into Phyloncology platform.



- Platform maps to robust baseline cladograms to classify: Healthy, Transitional (early detection), Cancerous. All in real time.

# Competitive Advantage

---

- Universal cancer applicability
- Non-invasive and scalable
- Cost-effective compared to existing diagnostics
- Handles biological heterogeneity



# Scientific & Clinical Validation



- **Clear separation of healthy vs cancer cohorts**
- **Distinguishes primary vs metastatic disease**
- **Validated across multiple biological data types**
- **Successfully classifies physiological differences in serum data.**

Multiple peer-reviewed studies underpin methodology.

# Business Model

## Revenue Streams and Expansion

1

### Revenue

- Direct diagnostic fees (\$250 per screening, includes \$100 lab processing)
- Bundled multi-cancer packages

2

### Partnership

- Integrations with hospitals & labs
- Insurance reimbursement after regulatory approval

3

### Expansion

- Begin with U.S., then global rollout.

# OUR TEAM

---



**Dr. Mones Abu-Asab, PhD**

*Co-Founder  
Evolutionary and oncology  
expert*




**Mohamed Chaouchi, MS**

*Co-Founder  
Technological and strategy  
leader*

# Why Invest Now



- **Strong scientific foundation and IP**
- **Platform scalability across cancers**
- **Early mover advantage in evolutionary diagnostics**



## CALL TO ACTION

---

- **Seeking strategic investors and partners**
- **Join us in transforming cancer detection**